Lysine Acetylation, Cancer Hallmarks and Emerging Onco-Therapeutic Opportunities.
Meilan HuFule HeErik W ThompsonKostya Ken OstrikovXiaofeng DaiPublished in: Cancers (2022)
Acetylation, a reversible epigenetic process, is implicated in many critical cellular regulatory systems including transcriptional regulation, protein structure, activity, stability, and localization. Lysine acetylation is the most prevalent and intensively investigated among the diverse acetylation forms. Owing to the intrinsic connections of acetylation with cell metabolism, acetylation has been associated with metabolic disorders including cancers. Yet, relatively little has been reported on the features of acetylation against the cancer hallmarks, even though this knowledge may help identify appropriate therapeutic strategies or combinatorial modalities for the effective treatment and resolution of malignancies. By examining the available data related to the efficacy of lysine acetylation against tumor cells and elaborating the primary cancer hallmarks and the associated mechanisms to target the specific hallmarks, this review identifies the intrinsic connections between lysine acetylation and cancer hallmarks and proposes novel modalities that can be combined with HDAC inhibitors for cancer treatment with higher efficacy and minimum adverse effects.
Keyphrases
- histone deacetylase
- papillary thyroid
- squamous cell
- healthcare
- gene expression
- lymph node metastasis
- squamous cell carcinoma
- dna methylation
- amino acid
- stem cells
- childhood cancer
- machine learning
- high resolution
- genome wide
- single cell
- electronic health record
- small molecule
- artificial intelligence
- protein protein
- combination therapy